Fundraising FoxCardioFocus
Marlborough, US · Delaware corporation · 13 known investors
Find your way into CardioFocus
Sign up to see every warm intro you have to CardioFocus
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CardioFocus team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control. The company's portfolio includes the Centauri™ System and next-generation platforms designed for diverse ablation strategies in electrophysiology practices worldwide.
Founders & leadership
LJ
Lauren JenningsExecutive
WC
Warren ClarkExecutive
AR
Anjie RoldanVP Finance and Administration2001–2016Anjie Roldan is Executive Officer at CardioFocus, which develops Pulsed Field Ablation technologies for treating cardiac arrhythmias. She previously worked as a finance consultant advising startups on financial strategy, accounting operations, and investor relations.
WR
Warren R. Clark IIIExecutive
Board
BR
Bruce RobertsonBoard director
CK
Christopher KroegerBoard director
OA
Omar AmiranaBoard director
JG
James GarveyBoard director
PL
CL
Charles LarsonBoard director
Investors · 13
Saints Capitallisted by Saints CapitalDenver
How we know: Saints Capital's portfolio page · Not right? Tell us
SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20Mvia Paul LaViolette · board
How we know: SV Health Investors's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
SV Life SciencesreportedBoston
How we know: prnewswire.com · Not right? Tell us
Also in the syndicate · 7
First Alliance & Capital Invest, Ltd.Fletcher Spaght VenturesH.I.G. BioVenturesKBL Healthcare InvestorsKestrel Venture ManagementManatuck Hill PartnersThe Aurora Funds
Reported raises · per SEC filings
Form D private placements$128.7M disclosed across 10 of 11 rounds · 2011–2023
▶$27.2MraisedFeb 2023 · 4 investors · Other TechnologyRule 506(b)
▶$27.2MraisedFeb 2023 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David KhoDirector
- Charles LarsenDirector
- Stephan OgilvieExecutive Officer
- Bruce RobertsonDirector
- Scott FletcherExecutive Officer
- Gwen WatanabeDirector
- Offering amount
- $31.8M
- Amount sold
- $27.2M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedApr 2022 · 12 investors · Other TechnologyRule 506(b)
▶$4MraisedApr 2022 · 12 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Stephan OgilvieExecutive Officer
- Paul LaVioletteDirector
- Charles LarsenDirector
- Bruce RobertsonDirector
- Patrick WethingtonDirector
- Omar AmiranaDirector
- Burke BarrettExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $4M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedJul 2020 · 13 investors · Other TechnologyRule 506(b)
▶$12MraisedJul 2020 · 13 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul LaVioletteDirector
- Burke BarrettExecutive Officer, Director
- Omar AmiranaDirector
- Bruce RobertsonDirector
- Charles LarsenDirector
- Patrick WethingtonDirector
- Offering amount
- $15M
- Amount sold
- $12M
- Minimum investment
- $10K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2019 · 17 investors · BiotechnologyRule 506(b)
▶$8MraisedMay 2019 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- OMAR AMIRANADirector
- PAUL LAVIOLETTEDirector
- OMARI BOUKNIGHTExecutive Officer
- CHRISTOPHER A. KROEGERDirector
- GREG MADDENDirector
- BRUCE C. ROBERTSONDirector
- BURKE BARRETTExecutive Officer
- PATRICK WETHINGTONDirector
- CHARLES E. LARSENDirector
- Offering amount
- $12M
- Amount sold
- $8M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
▶$13MraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PATRICK WETHINGTONDirector
- WARREN R. CLARK, IIIExecutive Officer
- BURKE BARRETTExecutive Officer
- OMAR AMIRANADirector
- PAUL LAVIOLETTEExecutive Officer, Director
- GREG MADDENDirector
- BRUCE C. ROBERTSONDirector
- CHARLES E. LARSENDirector
- CHRISTOPHER A. KROEGERDirector
- Offering amount
- $21M
- Amount sold
- $13M
- Sales commissions
- $260K
- Placement agents
- TRUMP SECURITIES LLC
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.2MraisedMar 2017 · 26 investors · BiotechnologyRule 506(b)
▶$20.2MraisedMar 2017 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAUL LAVIOLETTEExecutive Officer, Director
- WARREN CLARK, IIIExecutive Officer
- BRUCE C. ROBERTSONDirector
- CHRISTOPHER KROEGERDirector
- CHARLES LARSENDirector
- JAMES GARVEYDirector
- OMAR AMIRANADirector
- BURKE BARRETTExecutive Officer
- PATRICK J. WETHINGTONDirector
- Offering amount
- $32.1M
- Amount sold
- $20.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2016 · BiotechnologyRule 506(b)
▶$8MraisedMay 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- OMAR ANIRANADirector
- CHRISTOPHER A. KROEGERDirector
- CHARLES E. LARSENDirector
- WARREN R. CLARK, IIIExecutive Officer
- JAMES GARVEYDirector
- PAUL LAVIOLETTEDirector
- BRUCE C. ROBERTSONDirector
- Offering amount
- $12M
- Amount sold
- $8M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31.7MraisedJan 2015 · 32 investors · Other TechnologyRule 506(b)
▶$31.7MraisedJan 2015 · 32 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Bruce RobertsonDirector
- Lauren JenningsExecutive Officer
- Christopher KroegerDirector
- Omar AmiranaDirector
- Warren ClarkExecutive Officer
- James GarveyDirector
- Paul LaVioletteExecutive Officer, Director
- Stephen SagonExecutive Officer, Director
- Charles LarsenDirector
- Anjie RoldanExecutive Officer
- Offering amount
- $33.2M
- Amount sold
- $31.7M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Boston ScientificBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
ToperaAbbott's Lingo Glucose System is a continuous glucose monitoring device for non-insulin users aged 18+, designed to track glucose levels and support metabolic health decisions.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Companies working in the same space as CardioFocus.
In the news
Frequently asked questions
- What does CardioFocus do?
- CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control. The company's portfolio includes the Centauri™ System and next-generation platforms designed for diverse ablation strategies in electrophysiology practices worldwide.
- Who are CardioFocus's investors?
- CardioFocus's investors include BioBrit, Saints Capital, SV Health Investors, Accuitive Medical Ventures, Oxford Bioscience Partners, SV Life Sciences.
- How much funding has CardioFocus raised?
- CardioFocus has disclosed $128.7M raised across 10 of its 11 known rounds.
- Where is CardioFocus headquartered?
- CardioFocus is headquartered in Marlborough, US.